

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

 APPLICATION NO.
 FILING DATE
 FIRST NAMED INVENTOR
 ATTORNEY DOCKET NO.
 CONFIRMATION NO.

 09/648,389
 08/25/2000
 David Pinsky
 62683/JPW/JML
 5890

 7590
 05/06/2003
 05/06/2003
 05/06/2003
 05/06/2003
 05/06/2003

Cooper & Dunham LLP 1185 Avenue of the Americas New York, NY 10036 EXAMINER
GIBBS, TERRA C

ART UNIT PAPER NUMBER

1635

DATE MAILED: 05/06/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)
09/648,389	PINSKY ET AL.
Examin r	Art Unit
Terra C. Gibbs	1635

-The MAILING DATE f this c mmunication appears n the cover sheet with the correspondence address --

THE REPLY FILED 15 April 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

condi Exam	tion for allowance; (2) a timely filed Notice of Appèal (with appeal fee); or (3) a timely filed Request for Continued ination (RCE) in compliance with 37 CFR 1.114.
	PERIOD FOR REPLY [check either a) or b)]
	The period for reply expires $\underline{3}$ months from the mailing date of the final rejection.
b) [The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
fee hav fee und (2) as s	densions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension be been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension der 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).
1.	A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2.🛛	The proposed amendment(s) will not be entered because:
(a) 🔯 they raise new issues that would require further consideration and/or search (see NOTE below);
(b	they raise the issue of new matter (see Note below);
(c) Methey are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) They present additional claims without canceling a corresponding number of finally rejected claims.
	NOTE: See Continuation Sheet.
3.	Applicant's reply has overcome the following rejection(s):
4.	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5.🔼	The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .
6.	The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7.🛛	For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
	The status of the claim(s) is (or will be) as follows:
	Claim(s) allowed: None.
	Claim(s) objected to: None.
	Claim(s) rejected: 16 and 18-27.
	Claim(s) withdrawn from consideration: None.
8.	The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.
9.	Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)
10.	Other: RAM SHUKLA PAM CHINKTA
	PRIMARY EXAMINER - UNER

U.S. Patent and Trademark Office

Continuation of 2. NOTE: The proposed new claims 28-36 drawn to a method of reducing ischemic damage using a compound inhibitor of Egr-1 wherein the compound is a peptide, a peptidomimetic compound, a nucleic acid molecule, a small molecule, an organic compound, an inorganic compound, or an antibody or fragment thereof would require further consideration and search.

Continuation of 5. does NOT place the application in condition for allowance because: The proposed amendment to pending claims 16, 18, 19, 25 and 27 would not overcome the 35 U.S.C. 112, first paragraph rejection for the reasons of record set forth in the Office Action mailed 1/9/03 in Paper No. 12. More specifically, the proposed amendment to pending claim 16, 18, 19, 25 and 27 encompass in vivo therapy and as discussed in the Office Action, undue experimentation would be required to practice the claimed invention.

RAM SHUKLA